Popular on TelAve
- Natalie Jean Releases Heartfelt Tribute Single "What They Didn't See" Honoring Late Friend and Lyricist Michael Peloso
- European Tech Startup RoarFun discovers a gap in the U.S. market with a branded racing simulator rental at Atlanta's MRO Americas Aviation Convention
- Premium Domain Name "Feedri.com" Now Available for Acquisition After $8,500 Offer
- **Award-Winning Dystopian Book Series Hitting Too Close to Home**
- NBA Legend Jeremy Lin, Benny Luo and Sy Huq Team Up to Executive Produce Powerful New Short Film "Ayo, Check Up!"
- Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement
- Carnegie Hall Hosts Theatrical Concert: El Dorado – A Musical Portrait of Edgar Allan Poe
- Men's Health Network Urges Memphis Community to Attend 2025 Men's Health Month Summit
- Spiritually Transformative Events Based on Bhagavad Gita – Path to a Fulfilling Life
- $10 Million Plan to Acquire Successful Remote Lottery Platform: Expanding Global Footprint into Live Entertainment: Lottery.com (Stock Symbol: LTRY)
Similar on TelAve
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers
- Remember Internet Pioneers NetCom Solutions & Network Solutions? Founder Emmit J. McHenry is Now Leading the Emerging Cybersecurity Firm Cycurion
- LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
- PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
- VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
- Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
TelAve News/10865546
~ Caliway Biopharmaceuticals to Present Latest R&D Progress and Pipeline Development at 2025 BIO International Convention
Caliway Biopharmaceuticals (TWSE: 6919) has announced its participation in the highly anticipated 2025 BIO International Convention, set to take place from June 16 to 19 in Boston, U.S.A. The company's Vice President, April Yuan, will be delivering an oral presentation on June 17, highlighting Caliway's latest advancements in research and development as well as updates on their pipeline.
The presentation will focus on CBL-514, a first-in-class injectable drug candidate for targeted fat reduction in large areas. This includes its development for multiple indications such as subcutaneous fat reduction, cellulite, and Dercum's disease.
In addition to these updates, Caliway will also be sharing preclinical data on a potential new indication for CBL-514: weight rebound management through a combination therapy with GLP-1 receptor agonists. This is significant as post-discontinuation weight rebound has become a major concern for patients using GLP-1 treatments globally. Studies have shown that only 10% of patients are able to maintain weight loss after stopping GLP-1 therapy.
Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate. This suggests that CBL-514 may help maintain weight loss outcomes after GLP-1 therapy by directly targeting the root cause of subcutaneous fat through selective induction of adipocyte apoptosis. It has the potential to serve as a complementary combination therapy with GLP-1 treatments, providing both systemic weight loss and precise body contouring.
More on TelAve News
Caliway plans to submit an IND application for this new indication to the U.S. FDA in Q4 2025. CEO Vivian Ling believes that post-weight-loss weight rebound is a promising unmet market need and that CBL-514 has the potential to enhance the overall treatment impact and long-term value by reshaping and maintaining outcomes through localized fat reduction.
The BIO International Convention is the largest and most influential biotechnology event in the world, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation exchange, and investment.
Caliway's presentation at BIO 2025 will take place on Tuesday, June 17 at 11:45 AM – 12:00 PM (EDT) in Room 154 at the Boston Convention & Exhibition Center. April Yuan, VP of Caliway Biopharmaceuticals, will be the speaker. More information about the session can be found on the convention's website.
CBL-514 is a first-in-class small-molecule drug developed by Caliway that targets subcutaneous fat without causing any systemic side effects on the central nervous system, cardiovascular system, or respiratory system. As of May 2025, it has completed 10 clinical trials with a total of 520 subjects and has met all efficacy and safety endpoints.
More on TelAve News
Caliway is currently investigating multiple indications for CBL-514 including non-surgical fat reduction, moderate-to-severe cellulite, and weight rebound management through a combination therapy with GLP-1-based treatments. They are also studying CBL-514D for additional indications such as Dercum's disease.
Caliway Biopharmaceuticals (TWSE:6919) is a clinical-stage biopharmaceutical company focused on breakthrough drug discovery of novel small-molecule therapeutics. Their goal is to become an innovative leader in aesthetic medicine and other diseases. For more information about Caliway Biopharmaceuticals, please visit their website.
Disclaimer: This article and related information on this site contain forward-looking statements that are subject to risks and uncertainties. These statements are based on current expectations, estimates, and projections about the industry, markets in which Caliway operates, and management's beliefs and assumptions. Actual results may differ materially from those expressed or implied in these statements due to various factors. Caliway does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date of this article.
Caliway Biopharmaceuticals (TWSE: 6919) has announced its participation in the highly anticipated 2025 BIO International Convention, set to take place from June 16 to 19 in Boston, U.S.A. The company's Vice President, April Yuan, will be delivering an oral presentation on June 17, highlighting Caliway's latest advancements in research and development as well as updates on their pipeline.
The presentation will focus on CBL-514, a first-in-class injectable drug candidate for targeted fat reduction in large areas. This includes its development for multiple indications such as subcutaneous fat reduction, cellulite, and Dercum's disease.
In addition to these updates, Caliway will also be sharing preclinical data on a potential new indication for CBL-514: weight rebound management through a combination therapy with GLP-1 receptor agonists. This is significant as post-discontinuation weight rebound has become a major concern for patients using GLP-1 treatments globally. Studies have shown that only 10% of patients are able to maintain weight loss after stopping GLP-1 therapy.
Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate. This suggests that CBL-514 may help maintain weight loss outcomes after GLP-1 therapy by directly targeting the root cause of subcutaneous fat through selective induction of adipocyte apoptosis. It has the potential to serve as a complementary combination therapy with GLP-1 treatments, providing both systemic weight loss and precise body contouring.
More on TelAve News
- Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
- DivX Enhances AVI Playback Resources; Simplifies Guide to Playing AVI Files with DivX Software
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
- Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
Caliway plans to submit an IND application for this new indication to the U.S. FDA in Q4 2025. CEO Vivian Ling believes that post-weight-loss weight rebound is a promising unmet market need and that CBL-514 has the potential to enhance the overall treatment impact and long-term value by reshaping and maintaining outcomes through localized fat reduction.
The BIO International Convention is the largest and most influential biotechnology event in the world, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation exchange, and investment.
Caliway's presentation at BIO 2025 will take place on Tuesday, June 17 at 11:45 AM – 12:00 PM (EDT) in Room 154 at the Boston Convention & Exhibition Center. April Yuan, VP of Caliway Biopharmaceuticals, will be the speaker. More information about the session can be found on the convention's website.
CBL-514 is a first-in-class small-molecule drug developed by Caliway that targets subcutaneous fat without causing any systemic side effects on the central nervous system, cardiovascular system, or respiratory system. As of May 2025, it has completed 10 clinical trials with a total of 520 subjects and has met all efficacy and safety endpoints.
More on TelAve News
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
Caliway is currently investigating multiple indications for CBL-514 including non-surgical fat reduction, moderate-to-severe cellulite, and weight rebound management through a combination therapy with GLP-1-based treatments. They are also studying CBL-514D for additional indications such as Dercum's disease.
Caliway Biopharmaceuticals (TWSE:6919) is a clinical-stage biopharmaceutical company focused on breakthrough drug discovery of novel small-molecule therapeutics. Their goal is to become an innovative leader in aesthetic medicine and other diseases. For more information about Caliway Biopharmaceuticals, please visit their website.
Disclaimer: This article and related information on this site contain forward-looking statements that are subject to risks and uncertainties. These statements are based on current expectations, estimates, and projections about the industry, markets in which Caliway operates, and management's beliefs and assumptions. Actual results may differ materially from those expressed or implied in these statements due to various factors. Caliway does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date of this article.
Filed Under: Business
0 Comments
Latest on TelAve News
- LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
- csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
- PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
- Let's Talk Series: At the Crossroads: Immigration Today
- Cyta Cyprus Selects Axiros' AXESS Platform for Cloud-Native, Data-Driven Device Management
- DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions
- Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
- VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
- Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
- Urgent Reform Demanded to Stop Child Abuse in Youth Behavioral Facilities
- Cyrus O'Leary's Mini Cream Pies - The Latest Dessert Innovation from Sara Lee Frozen Bakery Delivers Indulgence in Single-Servings
- Emerge Apps Launches Mod Performance Suite: A New Era of Work Comp Selling for Insurance Agents
- Imagine waking up every day knowing you can earn $, and actually making it happen. Are you ready to change your life? Let's get started!
- ETH Price Prophecy: Is $3,000 Within Reach? — HASHJ Best Cloud Mining Platform Focuses on Gas-Optimized Mining
- Mental Health Watchdog Calls Baker Acting of Children in Florida a Parental Rights Violation
- Injured While Using Rideshare?
- Wealthywet's Miami Swim Week 2025 Debut Signals a New Era of Luxury in Swimwear
- Luxury Waterfront Home in Porto Sol Community Now Available Through Innovative "Name Your Price" Approach
- BREAKING CONSUMER ALERT: Carvana's "Certified" Luxury SUV Buyer Exposes Legal & Mechanical Trauma 'Presses' Charges of Duress, Deception, and Delay
- JMC Princess Announces Release of Empowering New Single "PRETTY" – A Summer Anthem for Young Girls Everywhere